The team at the University of Hull have reviewed recent scientific papers on a particular type of drug, called arginine methylation inhibitors, and their targets.
The idea that arginine methylation is an important player in cancer has gained much weight in the past few years and this is underscored by the fact that major pharmaceutical companies have recently launched clinical trials with drugs that inhibit arginine methylation in the setting of various cancers.
The authors have found that there is great interest in developing the understanding of the mechanisms of action of these drugs. They have focused specifically on brain tumours and conclude that there is excellent potential for these drugs to be used as new therapeutic tools, as silver bullets, against brain tumours.
They have included recommendations on how future basic and clinical research should be designed to maximise the potential and the impact of this new type of drug to improve the outcome for brain tumour patients.
To read the publication in full please CLICK HERE.
This is the first published paper for Antonia and comes just a few months in from her starting her PhD placement. To see more about the research she is undertaking please CLICK HERE.